Previous close | 54.95 |
Open | 54.86 |
Bid | 53.80 x 1300 |
Ask | 55.78 x 1800 |
Day's range | 54.86 - 55.33 |
52-week range | 44.35 - 56.22 |
Volume | |
Avg. volume | 7,960,328 |
Market cap | 80.955B |
Beta (5Y monthly) | 0.78 |
PE ratio (TTM) | 67.39 |
EPS (TTM) | 0.82 |
Earnings date | 30 Jan 2024 - 05 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 60.72 |
Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.